Showing 8831-8840 of 9459 results for "".
- Neutrogena Sunscreens Awarded NEA Seal of Acceptancehttps://practicaldermatology.com/news/neutrogena-sunscreens-awarded-nea-seal-of-acceptance/2458928/The National Eczema Association (NEA) awarded its Seal of Acceptance to five Neutrogena sunscreens. This recognition is given to product innovations that help improve the quality of life for people with eczema, empowering consumers to make informed eczema purchase decisions. The fol
- FDA Grants Breakthrough Therapy Designation for Actemra in Systemic Sclerosishttps://practicaldermatology.com/news/fda-grants-breakthrough-therapy-designation-for-actemra-in-systemic-sclerosis/2458929/Genentech, a member of the Roche Group, was granted FDA Breakthrough Therapy Designation status for Actemra® (tocilizumab) for systemic sclerosis, also known as scleroderma. This designation is intended to expedite the development and review of medicines with early signals of poten
- NIH Funding Often Does Not Match Disease Burden for Dermatologic Conditionshttps://practicaldermatology.com/news/nih-funding-often-does-not-match-disease-burden-for-dermatologic-conditions/2458930/A new analysis of funding prioritization by the National Institutes of Health for skin disease offers a glimpse of cutaneous skin disease on a national level, with some disease states being possibly underfunded. Examining the relationship between dermatologic research funding and skin disease bur
- FDA Clears Alevicyn SG Antipruritic Spray Gel from Oculus Innovative Scienceshttps://practicaldermatology.com/news/fda-clears-alevicyn-sg-antipruritic-spray-gel-from-oculus-innovative-sciences/2458933/The FDA granted 510(k) clearance to Oculus Innovative Sciences, Inc. for Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications. The Alevicyn SGprescription product, using Microcyn(R) Technology, is indicate
- Radiesse from Merz Aesthetics Approved for Handshttps://practicaldermatology.com/news/radiesse-from-merz-aesthetics-approved-for-hands/2458934/Radiesse® from Merz Aesthetics received FDA approval for hand augmentation to correct volume loss in the dorsum of the hands. Radiesse® provides an immediate volumizing effect and can help to reduce the prom
- ASDSA Supports FDA Fillers Directivehttps://practicaldermatology.com/news/asdsa-supports-fda-fillers-directive/2458935/A recent FDA directive that soft-tissue filler manufacturers include additional precautions on product labels underscores the importance of patients seeking expert physicians for their treatments, according to the American Society for Dermatologic Surgery Association (ASDSA). The FDA is a
- Chief Academy Convenes in San Antoniohttps://practicaldermatology.com/news/chief-academy-convenes-in-san-antonio/2458938/The 2015 Chief Academy convened this month on the campus of the University of Texas Health Science Center - San Antonio, marking a move for the meeting from its 7-year home in Chicago. Dr. Vineet Mishra, Director of Mohs Surgery and Procedural Dermatology as w
- The American Academy of Dermatology Elects New Officers and Board Membershttps://practicaldermatology.com/news/the-american-academy-of-dermatology-elects-new-officers-and-board-members/2458941/The American Academy of Dermatology (AAD) announced the results of its annual election. The newly elected officers and board members will lead the AAD, which represents more than 19,000 physicians. These officers and board members also will hold the same positions for the American Academy of Derm
- Encore Dermatology, Inc.: A New Specialty Dermatology Company Launcheshttps://practicaldermatology.com/news/encore-dermatology-inc-a-new-specialty-dermatology-company/2458942/Encore Dermatology, Inc. announced has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three established topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates. Encore Dermatology, Inc. is a privately
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su